Date: 2014-12-02
Type of information: Series B financing round
Company: AyoxxA Biosystems (Germany)
Investors: Wellington Partners Venture Capital (Germany), NRW.BANK (Germany), HTGF - High-Tech-Gründerfonds (Germany), KfW (Germany), b-to-v Partners (Germany), Creathor Venture (Germany), HR Ventures (Germany), private investors from the US and Europe, including Ayoxxa employees and two of Qiagen’s founders, BioMedPartners (Switzerland), Grazia Equity (Germany)
Amount: € 11.3 million
Funding type: series B financing round
Planned used: In line with the company’s strategy to commercialize its novel in-situ encoded bead array technology (IEBA), the funding will be used to scale-up the production of Ayoxxa’s proprietary biochips as well as to achieve international commercial readiness.
Others: * On December 2nd, 2014, Ayoxxa Biosystems, an international biotechnology company, announced the closing of a third round of Series B financing, bringing the total amount raised to 11.3 Mio. EUR in 2014. An additional 2.3 Mio. EUR were now invested by BioMedPartners AG, Basel and Grazia Equity GmbH, based in Stuttgart, Germany. Both leading European venture capital firms joined the group of established AYOXXA investors, who successfully closed second round in June 2014. * On July 10th, 2014, Ayoxxa Biosystems completed a € 9,0m Series B financing round by the end of June 2014. All of the company’s existing investors (High-Tech Gründerfonds, KfW, NRW.BANK, Wellington Partners Venture Capital and private investors) took part, along with new investors b-to-v Partners AG, Creathor Venture and HR Ventures. In addition several private investors from the US and Europe, including Ayoxxa employees and two of Qiagen’s founders, joined this financial round.
Therapeutic area: Technology - Services - Diagnostic
